EVALUATION OF SAFETY OF DRUG THERAPY IN CLINICAL PRACTICE
Abstract
the present review is devoted to an actual problem of safety of pharmacotherapy in clinical practice; the particular attention is paid to the state of this problem in pediatrics. Information about pharmacovigilance is proposed; criteria of definition, methods of collecting (their advantages and limitations), account and analysis of the adverse reactions of drugs in post-marketing period are described. The off label use of drugs in children and a role of clinical pharmacologist in the adverse reactions of drugs monitoring in a hospital is discussed.
About the Authors
M. N. Kostyleva
Russian Children's Clinical Hospital, Ministry of Health of the Russian Federation, Moscow;
The Russian National Research Medical University named after N.I. Pirogov of the Ministry
of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
Yu. B. Belousov
The Russian National Research Medical University named after N.I. Pirogov of the Ministry of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
A. N. Gratsianskaya
Russian Children's Clinical Hospital, Ministry of Health of the Russian Federation, Moscow;
The Russian National Research Medical University named after N.I. Pirogov of the Ministry
of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
S. S. Postnikov
Russian Children's Clinical Hospital, Ministry of Health of the Russian Federation, Moscow;
The Russian National Research Medical University named after N.I. Pirogov of the Ministry
of Health of the Russian Federation, Moscow
Russian Federation
Russian Federation
References
1. Bezopasnost' lekarstv i farmakonadzor. 2008; 1: 17; 2009; 1: 13.
2. Kosenko V.V., Glagolev S.V. Organizacija sistemy monitoringa bezopasnosti zaregistrirovannyh lekarstvennyh preparatov v Rossijskoj Federacii. Vestnik Roszdravnadzora. 2012; 5.
3. Lepahin V.K., Sturov N.V., Astahova A.V. Sravnitel'nyj analiz metodov registracii neblagoprijatnyh pobochnyh reakcij lekarstvennyh sredstv. Klinicheskaja farmakologija i terapija. 2008; 17 (5): 49-53.
4. Aagaard I., Christensen A., Hansen E. Information about adverse drug reactions reported in children: a qualitative review of empirical studies. Br. J. Clin. Pharmac. 2010; 70: 481-491.
5. Aldea A., Garcia Sanchez-Colomer M., Fernandez Quintana E et al. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. Eur. J. Clin. Pharmacol. Sep 2012; 68 (9): 1329-38.
6. Bellis J., Kirkham J., Gallagher R.M. et al. Adverse drug reactions and off-label and unlicensed medicines in children: a nested casecontrol study of paediatric inpatients. Arch Dis Child. 2013; 98.
7. Carleton B.C.et al. Paediatric adverse drug reaction reporting: understanding and future directions. Can. J. Pharmacol. 2007; 14 (1): 45-47.
8. Ciccone G.K., Holdcroft А. Drugs and sex differences: a review of drugs relating to anaesthesia. British Journal of Anaesthesia. 1999; 82: 255-265.
9. Conroy S., Choonara I., Impicciatore P. et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ. 2000; 320: 79-82.
10. Ghamar Taj Khotaei, Fatemex Fattahi, Zahra Pourpak et al. Adverse reactions to antibiotics in hospitalized Iranian children. J. Microbiol. Immunol. Infect. 2008; 41: 160-164
11. http://www.who.int
12. Impicciatore P., Choonara I., Clarcson A. et al. Incidence of adverse drug reactions in paediatric in/out patients. A systematic review and meta-analysis of prospective studies. Br. J. Clin. Pharmacol. 2001; 52: 77-83.
13. Impicciatore Piero, Mohn Angelika, Chiarelli F. et al. Adverse drug reactions to off-label drugs on a paediatric ward: an Italian prospective pilot study. Pediatric & perinatal drug therapy. 2002; 5: 1.
14. Lowry F. History of atopy may predict serious adverse drug reactions. American College of Allergy, Asthma& Immunology. Annual Scientific Meeting: abstract. November 2012; 22.
15. Martinez-Mir I., Garcia-Lopez M., Palop V. A prospective study of adverse drug reactions in hospitalized children. Clinical Pharmacology. 1999; 47: 681-688.
16. Miller M.A. Gender-based differences in the toxicity of pharmaceuticals-The Food and Drug Administration’s // Perspective International Journal of Toxicology. 2001; 20: 149-152.
17. Moore N. The role of the clinical pharmacologist in the management of adverse drug reactions. Drug Safety. 2001; 24 (1): 1-7.
18. Morales-Olivas F.J., Martinez-Mir I., Ferrer J.M et al. Adverse drug reactions in children reported by means of the yellow card in Spain. Journal of Clinical Epidemiology. 2000; 53 (10): 1076-1080.
19. Naranjo C.A., Busto U., Sellers E.M. et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981; 30 (2): 239-45.
20. Pandolfini C., Bonati M. A literature review on off-label drug use in children. Eur. J. Pediatr. 2005; 164: 552-8.
21. Pandolfini C., Provasi D., Rocchi F. et al. The off-label use of drugs in Italy; a prospective, observational, multicentre study. Acta Paediatr. 2002; 91: 339-347.
22. Practical Drug Safety from A to Z. 2009; 250-251.
23. Priyadharsini R., Surendiran A., Adithan C et al. A study of adverse drug reactions in pediatric patients. J. Pharmacol. Pharmacother. 2011; 2: 277-280.
24. Progress in allergy and clinical immunology: proceeding of the XVIth International Congress of allergology and clinical immunology. Cancun. Mexico.1997; 4: 352-358.
25. Rashed A.N., Wong I.C., Cranswick N et al. Risk factors associated with adverse drug reactions in hospitalized children: international multicentre study. Eur. J. Clin. Pharmacol. 2012 May; 68 (5): 801-10.
26. Riordan F.A.I. Use of unlabelled and off-license drugs in children. BMJ. 2000; 320: 1210.
27. Rodenburg E.M., Stricker B.H.Ch, Visser L.E. Sex-related differences in hospital admissions attributed to adverse drug relactions in the Netherlands. British Journal of Clinical Pharmacology. 2011; 71 (1): 95-104.
28. Shehab N., Patel P., Srinivasan A. Emergency depertment visits for antibiotic-associated adverse events. Clinical Infectious Dis. 2008; 47: 735-43.
29. Smyth R., Gardon E., Kirkham J. et al. Adverse drug reactions in children-a systematic review. PloS One. 2012; 7 (3): e44016.
30. Stafford R.S. Regulating off-label drug use-rethinking the role of the FDA. NEJM. 2008; 358: 1427-1429.
31. Star Kristina. Safety of Medication in Paediatrics. Acta Universitatis Upsaliensis Uppsala. 2013; 16-17.
32. Star Kristina, Noren G. Niklas, Nordin Karin, Edwards I. Ralf. Suspected adverse drug reactions reported for children wordwilde: an exploratory study, using VigiBase. Drug Safety; 2011; 34 (5): 415-428.
33. Temple M.E., Robinson R.F., Miller J.C. et al. Frequency and preventability of adverse drug reactions in paediatric patients. Drug Saf. 2004; 27 (11): 819-29.
34. Turner S., Longworth A., Nunn A.J. et al. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ. 1998; 316: 343-345.
35. Venulet J. Role and place of causality assessment. Pharma Drug safety. 1992; 1 (225): 2234.
36. Zopf Y.C., Rabe A., Neubert K. et al. Women encounter ADRs more often than do men. Eur. J. Clin. Pharmacol. 2008; 64: 999-1004.
Review
For citations:
Kostyleva M.N., Belousov Yu.B., Gratsianskaya A.N., Postnikov S.S. EVALUATION OF SAFETY OF DRUG THERAPY IN CLINICAL PRACTICE. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2014;7(1):27-32. (In Russ.)
Views:
875
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 